Abadir Sylvia, Sarquella-Brugada Georgia, Mivelaz Yvan, Dahdah Nagib, Miró Joaquim
Service de cardiologie pédiatrique, hôpital Sainte-Justine, 3175, chemin de Côte-Sainte-Catherine, Montréal, Québec H3T 1C5, Canada.
Arch Cardiovasc Dis. 2009 Jun-Jul;102(6-7):569-82. doi: 10.1016/j.acvd.2009.04.006. Epub 2009 Jul 28.
Interventional paediatric and congenital cardiology is expanding at a rapid pace. Validated techniques (such as aortic or pulmonary valve dilatations and occlusion of persistent ductus arteriosus and atrial septal defects) are improving thanks to the use of smaller introducers and sheaths, low-profile balloons and novel devices. Moreover, catheter-based interventions have emerged as an attractive alternative to surgery in other fields: pulmonary valve replacement, balloon and stent implantation for native and recurrent coarctation, and percutaneous closure of ventricular septal defects. On the other hand, percutaneous interventions in the paediatric population may be limited by patient size or the anatomy of the defect. Hybrid approaches involving both cardiac interventionists and surgeons are being developed to overcome these limitations. Based on a better understanding of cardiac development, fetal cardiac interventions are being attempted in order to alter the history of severe obstructive lesions. Finally, some interventional procedures still carry a low success rate-for example, pulmonary vein stenosis, even with the use of conventional stents. Biodegradable stents and devices are being developed and may find an application in this setting as well as in others. The purpose of this review is to highlight the advances in paediatric interventional cardiology since the beginning of the third millennium.
小儿及先天性心脏病介入治疗正在迅速发展。由于使用了更小的导管鞘、低轮廓球囊和新型器械,一些经过验证的技术(如主动脉或肺动脉瓣扩张术以及动脉导管未闭和房间隔缺损封堵术)正在不断改进。此外,基于导管的介入治疗在其他领域已成为一种有吸引力的手术替代方案:肺动脉瓣置换术、针对原发性和复发性主动脉缩窄的球囊及支架植入术以及室间隔缺损的经皮封堵术。另一方面,儿科患者的经皮介入治疗可能会受到患者体型或缺损解剖结构的限制。为克服这些限制,正在开发心脏介入医生和外科医生共同参与的杂交手术方法。基于对心脏发育的更深入了解,正在尝试进行胎儿心脏介入治疗,以改变严重阻塞性病变的病程。最后,一些介入手术的成功率仍然较低——例如,即使使用传统支架,肺静脉狭窄的治疗成功率也较低。可生物降解支架和器械正在研发中,可能在这种情况以及其他情况下得到应用。本综述的目的是突出自第三个千年伊始小儿介入心脏病学所取得的进展。